Since PD-1 checkpoint blockades do not significantly benefit patients with relapsed glioblastoma in OS compared with bevacizumab, exploring candidate targets related to the immune response may provide new strategies associated with promoting the clinical efficacy of PD-1/PD-L1 checkpoint blockades. The gene discussed is CD274; the disease is glioblastoma.